Search

Your search keyword '"D'Arena, Giovanni"' showing total 37 results
Start Over Author "D'Arena, Giovanni" Journal leukemia & lymphoma
37 results on '"D'Arena, Giovanni"'

1. Oxidative stress in chronic lymphocytic leukemia: still a matter of debate

Author

D’Arena, Giovanni, primary, Seneca, Elisa, additional, Migliaccio, Ilaria, additional, De Feo, Vincenzo, additional, Giudice, Aldo, additional, La Rocca, Francesco, additional, Capunzo, Mario, additional, Calapai, Gioacchino, additional, Festa, Agostino, additional, Caraglia, Michele, additional, Musto, Pellegrino, additional, Iorio, Eugenio Luigi, additional, and Ruggieri, Vitalba, additional

Published
2018
Full Text
View/download PDF

2. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients

Author

D’Arena, Giovanni, primary, Simeon, Vittorio, additional, Laurenti, Luca, additional, Cimminiello, Michele, additional, Innocenti, Idanna, additional, Gilio, Michele, additional, Padula, Angela, additional, Vigliotti, Maria Luigia, additional, De Lorenzo, Sonya, additional, Loseto, Giacomo, additional, Passarelli, Anna, additional, Di Minno, Matteo Nicola Dario, additional, Tucci, Marco, additional, De Feo, Vincenzo, additional, D’Auria, Fiorella, additional, Silvestris, Francesco, additional, Di Minno, Giovanni, additional, and Musto, Pellegrino, additional

Published
2017
Full Text
View/download PDF

3. Oxidative stress in chronic lymphocytic leukemia: still a matter of debate.

Author

D'Arena, Giovanni, Seneca, Elisa, Migliaccio, Ilaria, De Feo, Vincenzo, Giudice, Aldo, La Rocca, Francesco, Capunzo, Mario, Calapai, Gioacchino, Festa, Agostino, Caraglia, Michele, Musto, Pellegrino, Iorio, Eugenio Luigi, and Ruggieri, Vitalba

Subjects
*CHRONIC lymphocytic leukemia, *OXIDATIVE stress, *CARCINOGENESIS, *REACTIVE oxygen species, *DEBATE
Abstract

There is a large body of evidence showing a strong correlation between carcinogenesis of several types of human tumors, including chronic lymphocytic leukemia (CLL), and oxidative stress (OS). The mechanisms by which OS may promote cancer pathogenesis have not been completely deciphered yet and, in CLL, as in other neoplasms, whether OS is a primary cause or simply a downstream effect of the disease is still an open question. It has been demonstrated that, in CLL, OS concomitantly results from increased reactive oxygen species (ROS) production, mainly ascribable to CLL cells mitochondrial activity, and impaired antioxidant defenses. Interestingly, OS evaluation in CLL patients, at diagnosis, seems to have a prognostic significance, thus getting new insights in the biological comprehension of the disease with potential therapeutic implications. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

4. Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia

Author

De Luca, Luciana, primary, D’Arena, Giovanni, additional, Simeon, Vittorio, additional, Trino, Stefania, additional, Laurenzana, Ilaria, additional, Caivano, Antonella, additional, La Rocca, Francesco, additional, Villani, Oreste, additional, Mansueto, Giovanna, additional, Deaglio, Silvia, additional, Innocenti, Idanna, additional, Laurenti, Luca, additional, Molica, Stefano, additional, Pietrantuono, Giuseppe, additional, De Stradis, Angelo, additional, Del Vecchio, Luigi, additional, and Musto, Pellegrino, additional

Published
2016
Full Text
View/download PDF

5. Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience

Author

Laurenti, Luca, primary, Autore, Francesco, additional, Innocenti, Idanna, additional, D’Arena, Giovanni, additional, Coscia, Marta, additional, Mondello, Patrizia, additional, Chiusolo, Patrizia, additional, Bellesi, Silvia, additional, Efremov, Dimitar G., additional, Sica, Simona, additional, and Mauro, Francesca Romana, additional

Published
2016
Full Text
View/download PDF

6. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients.

Author

D'Arena, Giovanni, Simeon, Vittorio, Laurenti, Luca, Cimminiello, Michele, Innocenti, Idanna, Gilio, Michele, Padula, Angela, Vigliotti, Maria Luigia, De Lorenzo, Sonya, Loseto, Giacomo, Passarelli, Anna, Di Minno, Matteo Nicola Dario, Tucci, Marco, De Feo, Vincenzo, D'Auria, Fiorella, Silvestris, Francesco, Di Minno, Giovanni, and Musto, Pellegrino

Subjects
*HEMATOLOGIC malignancies, *AUTOIMMUNE disease treatment, *RITUXIMAB, *INTRAVENOUS therapy, *ADVERSE health care events, *CHRONIC lymphocytic leukemia, *THERAPEUTICS
Abstract

Rituximab is an effective treatment for CD20+B-cell malignancies and autoimmune disorders. However, adverse drug reactions (ADRs) may occur after rituximab infusion, causing, in rare cases, its discontinuation. In this multicenter, retrospective study, among 374 patients treated with rituximab i.v., 23.5% experienced ADRs. Mean follow-up was 20.6 months (range 8–135). Overall, ADRs were significantly more frequent in non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemias (25–35.9%), than in autoimmune diseases (9.4–17.5%) (p<.0001). Grade 3–4 toxicity was observed in eight patients (2.1%), and in four of them (1% of all patients) definitive drug discontinuation was necessary. Interestingly, three groups of patients with different risk of developing ADR were identified, according to a predictive heat-map developed combining four parameters (splenomegaly, history of allergy, hemoglobin levels and gender) selected by multivariate analysis. This model may be useful in identifying patients at higher risk of ADRs, needing appropriate preventing therapies. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

7. Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia.

Author

De Luca, Luciana, D'Arena, Giovanni, Simeon, Vittorio, Trino, Stefania, Laurenzana, Ilaria, Caivano, Antonella, La Rocca, Francesco, Villani, Oreste, Mansueto, Giovanna, Deaglio, Silvia, Innocenti, Idanna, Laurenti, Luca, Molica, Stefano, Pietrantuono, Giuseppe, De Stradis, Angelo, Del Vecchio, Luigi, and Musto, Pellegrino

Subjects
*LYMPHOCYTIC leukemia, *MULTIVARIATE analysis, *B cells, *SERUM, *LYMPHOCYTES, *TUMORS, *DIAGNOSIS
Abstract

Microvescicles (MV) are shedding particles released by normal and neoplastic cells, whose levels in biological fluids highlight their potential role as disease biomarkers and therapeutic targets. By analyzing 131 newly diagnosed chronic lymphocytic leukemia (CLL), we found that the absolute number of serum CLL MV was significantly higher than in controls, in particular in advanced stages of disease. In addition, CD19 + and CD37+, B-cell derived MV, significantly correlated with high tumor burden. Absolute MV number cutoff selected by ROC analysis distinguished Rai stage 0 patients with shorter time to treatment (TTT) from those with more stable disease. Likewise, in the entire cohort, two groups of patients with different overall survival (OS) and different TTT were identified. At multivariate analysis, serum MV independently predicted for OS (along with Rai stage) and TTT (along with Rai stage, lymphocytes and CD38). In conclusion, circulating MV represent a new potential prognostic biomarker in CLL. [ABSTRACT FROM PUBLISHER]

Published
2017
Full Text
View/download PDF

9. More on spontaneous regression of chronic lymphocytic leukemia: two new cases and potential role of lamivudine in a further patient with advanced disease and hepatitis B virus infection

Author

D’Arena, Giovanni, primary, Guariglia, Roberto, additional, Pietrantuono, Giuseppe, additional, Villani, Oreste, additional, Martorelli, Maria Carmen, additional, Mansueto, Giovanna, additional, Criscuolo, Clelia, additional, Pierri, Teresa, additional, Musto, Clelia, additional, and Musto, Pellegrino, additional

Published
2014
Full Text
View/download PDF

10. Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey

Author

D’Arena, Giovanni, primary, Laurenti, Luca, additional, Coscia, Marta, additional, Cortelezzi, Agostino, additional, Chiarenza, Annalisa, additional, Pozzato, Gabriele, additional, Vigliotti, Maria Luigia, additional, Nunziata, Giuseppe, additional, Fragasso, Alberto, additional, Villa, Maria Rosaria, additional, Grossi, Alberto, additional, Selleri, Carmine, additional, Deaglio, Silvia, additional, La Sala, Antonio, additional, Del Poeta, Giovanni, additional, Simeon, Vittorio, additional, Aliberti, Luig, additional, De Martino, Laura, additional, Giudice, Aldo, additional, Musto, Pellegrino, additional, and De Feo, Vincenzo, additional

Published
2013
Full Text
View/download PDF

11. Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma

Author

Dell'olio, Matteo, primary, Potito scalzulli, Rosario, additional, Sanpaolo, Grazia, additional, Nobile, Michele, additional, Saverio mantuano, Francesco, additional, La sala, Antonio, additional, D'arena, Giovanni, additional, Miraglia, Eustachio, additional, Lucania, Anna, additional, Mastrullo, Lucia, additional, and Nicola, Cascavilla, additional

Published
2011
Full Text
View/download PDF

30. Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey.

Author

D'Arena, Giovanni, Laurenti, Luca, Coscia, Marta, Cortelezzi, Agostino, Chiarenza, Annalisa, Pozzato, Gabriele, Vigliotti, Maria Luigia, Nunziata, Giuseppe, Fragasso, Alberto, Villa, Maria Rosaria, Grossi, Alberto, Selleri, Carmine, Deaglio, Silvia, La Sala, Antonio, Del Poeta, Giovanni, Simeon, Vittorio, Aliberti, Luig, De Martino, Laura, Giudice, Aldo, and Musto, Pellegrino

Subjects
*CHRONIC lymphocytic leukemia treatment, *RESEARCH in alternative medicine, *NATUROPATHY, *CANCER patients, *DIET in disease, *CANCER & nutrition
Abstract

Complementary and alternative medicine (CAM) is common in patients with cancer and its use is steadily increasing over time. We performed a multicenter survey in which the use of CAM in 442 Italian patients with chronic lymphocytic leukemia (CLL), the commonest form of leukemia in Western countries, was assessed. Data were collected by means of a face-to-face standardized questionnaire with several items. Mean age was 69 years; 258 patients (58%) were male and 184 (42%) female. Seventy-three patients (16.5%) were found to be CAM users. The most common CAM therapies were green tea, aloe formulations and high dose vitamins. Predictors of CAM use were female gender, younger age, higher education level, internet availability and newspaper reading. The reasons for CAM popularity among these patients are complex. Given the number of patients combining therapy with CAM and its possible drug interactions, doctor interest as well as patient education about CAM should be improved. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

32. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study.

Author

D'arena, Giovanni, Gobbi, Paolo G., Broglia, Chiara, Sacchi, Stefano, Quarta, Giovanni, Baldini, Luca, Iannitto, Emilio, Falcone, Antonietta, Guariglia, Roberto, Pietrantuono, Giuseppe, Villani, Oreste, Martorelli, Maria Carmen, Mansueto, Giovanna, Sanpaolo, Grazia, Cascavilla, Nicola, and Musto, Pellegrino

Subjects
*CLINICAL trials, *MULTIPLE myeloma treatment, *DISODIUM pamidronate, *DRUG administration, *DISEASE progression
Abstract

A prospective, multicenter, randomized trial comparing pamidronate administration (60--90 mg once a month for 1 year) versus simple observation in 177 patients with asymptomatic myeloma was performed to explore whether the administration of this drug reduces the rate of and/or the time to progression to overt, symptomatic disease. No relevant side effects were recorded in pamidronate-treated patients. With a minimum follow-up of 5 years for live patients, there were 56/89 (62.9%%) progressions in the pamidronate-treated group and 55/88 (62.5%%) within the controls ( p == NS). Median time to progression was 46 and 48 months, respectively ( p == NS). Overall survival was also similar between the two groups. Skeletal-related events at the time of progression were observed in 40/55 (72.7%%) controls, but only in 22/56 (39.2%%) pamidronate-treated patients ( p == 0.009). In conclusion, the administration of pamidronate in asymptomatic myeloma, while reducing bone involvement at progression, did not decrease the risk of transformation and the time to progression into overt myeloma. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

33. Romiplostim for chronic lymphocytic leukemia-associated immune thrombocytopenia.

Author

D'Arena, Giovanni and Cascavilla, Nicola

Subjects
*LETTERS to the editor, *CHRONIC lymphocytic leukemia treatment, *DRUG efficacy
Abstract

A letter to the editor is presented which discusses the efficacy of romiplostim in the treatment of a 72-year-old patient diagnosed with chronic lymphocytic leukemia (CLL) associated with immune thrombocytopenia (IT).

Published
2011
Full Text
View/download PDF

34. More on spontaneous regression of chronic lymphocytic leukemia: two new cases and potential role of lamivudine in a further patient with advanced disease and hepatitis B virus infection.

Author

D'Arena, Giovanni, Guariglia, Roberto, Pietrantuono, Giuseppe, Villani, Oreste, Martorelli, Maria Carmen, Mansueto, Giovanna, Criscuolo, Clelia, Pierri, Teresa, Musto, Clelia, and Musto, Pellegrino

Subjects
*CHRONIC diseases, *LYMPHOCYTIC leukemia, *DISEASE remission, *CANCER remission
Abstract

The article presents case studies of two patients showing spontaneous remission (SR) to monoclonal B-lymphocytosis (MBL) after a diagnosis of early stage chronic lymphocytic leukemia (CLL) and the case of another patient with advanced CLL who experienced an unexpected remission before starting any specific anti-CLL therapy after being treated with with lamivudine for hepatitis B virus infection. The need for further research on CLL is discussed.

Published
2014
Full Text
View/download PDF

35. Letter to Editor.

Author

D'Arena, Giovanni, Valente, Vito, Luigia Vigliotti, Maria, Plastino, Giovanni, Tartarone, Alfredo, Iodice, Giovanni, Musto, Clelia, Matera, Rosella, and Di Renzo, Nicola

Subjects
*CHRONIC lymphocytic leukemia, *HEMODIALYSIS
Abstract

Presents a letter to the editor of the periodical 'Leukemia & Lymphoma' concerning the improvement of B-cell chronic lymphocytic leukemia (B-CLL) during hemodialysis. Role of endogenous production of factors involved in angiogenesis and apoptosis; Complications of hemodialysis; Molecular remission of B-CLL.

Published
2003

36. Letter to Editor.

Author

Vigliotti, Maria Luigia, Dell'Olio, Matteo, Romano, Gianpiero, Tartarone, Alfredo, D'Arena, Giovanni, Michele Carella, Angelo, and Di Renzo, Nicola

Subjects
STOMACH tumors, LYMPHOMAS, TUMOR treatment
Abstract

Presents a letter to the editor of the periodical 'Leukemia & Lymphoma; concerning the management of primary gastric lymphoma (PGL). Survival of patients with PGL; Clinical features; Types of treatment.

Published
2003

37. Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells.

Author

D'Arena, Giovanni, Ruggieri, Vitalba, D'Auria, Fiorella, La Rocca, Francesco, Simeon, Vittorio, Statuto, Teodora, Caivano, Antonella, Telesca, Donatella, Del Vecchio, Luigi, and Musto, Pellegrino

Subjects
*IMMUNOLOGICAL adjuvants, *CD20 antigen, *CHRONIC lymphocytic leukemia, *B cells, *FLOW cytometry
Abstract

The article discusses a study which examines the impact of lenalidomide, an immunomodulatory agent, on the CD20 antigen surface expression on chronic lymphocytic leukemia (CLL) B-cells using a flow cytometry (FC) analysis. Findings reveal the heterogeneous modulating effects of lenalidomide on CD20 expression in CLL B-cells. The outcomes' agreement with other studies are also mentioned.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results